Dr. Bruce Blazar, M.D

NPI: 1003842162
Total Payments
$1.1M
2024 Payments
$297,853
Companies
12
Transactions
84

Payment Breakdown by Category

Other$1.1M (94.2%)
Consulting$54,458 (4.9%)
Travel$5,577 (0.5%)
Education$3,610 (0.3%)
Food & Beverage$1,172 (0.1%)

Payments by Nature

Nature of Payment Amount Transactions Share
Acquisitions $1.1M 4 94.0%
Consulting Fee $54,458 21 4.9%
Travel and Lodging $5,577 29 0.5%
Education $3,610 1 0.3%
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,920 3 0.2%
Food and Beverage $1,172 26 0.1%

Top Paying Companies

Company Total Records Latest Year
Bayer HealthCare Pharmaceuticals Inc. $634,976 2 $0 (2022)
BlueRock Therapeutics LP $415,947 2 $0 (2024)
Incyte Corporation $13,283 16 $0 (2024)
Kadmon Corporation LLC $9,726 17 $0 (2019)
ModernaTX, Inc. $7,500 2 $0 (2022)
E.R. Squibb & Sons, L.L.C. $6,692 11 $0 (2018)
UCB SA $6,274 14 $0 (2017)
Promius Pharma LLC $5,939 8 $0 (2018)
Regeneron Pharmaceuticals, Inc. $5,110 7 $0 (2019)
SANOFI-AVENTIS U.S. LLC $4,395 3 $0 (2024)

Payment History by Year

Year Amount Transactions Top Company
2024 $297,853 4 BlueRock Therapeutics LP ($295,048)
2023 $127,566 3 BlueRock Therapeutics LP ($120,899)
2022 $509,273 4 Bayer HealthCare Pharmaceuticals Inc. ($498,128)
2021 $140,458 2 Bayer HealthCare Pharmaceuticals Inc. ($136,848)
2019 $12,088 19 Incyte Corporation ($8,768)
2018 $20,059 31 E.R. Squibb & Sons, L.L.C. ($6,692)
2017 $10,362 21 UCB SA ($6,274)

All Payment Transactions

84 individual payment records from CMS Open Payments — Page 1 of 4

Date Company Product Nature Form Amount Type
12/30/2024 BlueRock Therapeutics LP Acquisitions Cash or cash equivalent $295,048.16 General
02/22/2024 SANOFI-AVENTIS U.S. LLC REZUROCK (Drug) Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program In-kind items and services $500.00 General
Category: Oncology
02/07/2024 SANOFI-AVENTIS U.S. LLC REZUROCK (Drug) Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program In-kind items and services $250.00 General
Category: Oncology
01/22/2024 Incyte Corporation Consulting Fee Cash or cash equivalent $2,055.00 General
12/29/2023 BlueRock Therapeutics LP Acquisitions Cash or cash equivalent $120,898.67 General
09/26/2023 Incyte Corporation Consulting Fee Cash or cash equivalent $2,460.00 General
09/08/2023 Legend Biotech USA Inc. Consulting Fee Cash or cash equivalent $4,207.50 General
12/29/2022 Bayer HealthCare Pharmaceuticals Inc. Acquisitions Cash or cash equivalent $498,127.84 General
06/16/2022 ModernaTX, Inc. Consulting Fee Cash or cash equivalent $3,750.00 General
06/16/2022 ModernaTX, Inc. Consulting Fee Cash or cash equivalent $3,750.00 General
02/18/2022 SANOFI-AVENTIS U.S. LLC REZUROCK (Drug) Consulting Fee Cash or cash equivalent $3,645.00 General
Category: Oncology
10/01/2021 KADMON PHARMACEUTICALS LLC Education In-kind items and services $3,610.00 General
05/17/2021 Bayer HealthCare Pharmaceuticals Inc. Acquisitions Cash or cash equivalent $136,847.76 General
10/09/2019 Kadmon Corporation LLC Consulting Fee Cash or cash equivalent $390.00 General
07/02/2019 Regeneron Pharmaceuticals, Inc. Consulting Fee Cash or cash equivalent $730.00 General
04/30/2019 Incyte Corporation Consulting Fee Cash or cash equivalent $7,380.00 General
03/14/2019 Kadmon Corporation LLC Food and Beverage In-kind items and services $9.38 General
03/08/2019 Incyte Corporation Travel and Lodging Cash or cash equivalent $219.94 General
03/08/2019 Incyte Corporation Travel and Lodging Cash or cash equivalent $219.94 General
03/08/2019 Incyte Corporation Travel and Lodging Cash or cash equivalent $60.00 General
03/08/2019 Incyte Corporation Travel and Lodging Cash or cash equivalent $50.00 General
03/08/2019 Incyte Corporation Food and Beverage Cash or cash equivalent $49.99 General
03/08/2019 Incyte Corporation Food and Beverage Cash or cash equivalent $45.17 General
03/08/2019 Incyte Corporation Food and Beverage Cash or cash equivalent $24.99 General
03/08/2019 Incyte Corporation Food and Beverage Cash or cash equivalent $24.99 General

About Dr. Bruce Blazar, M.D

Dr. Bruce Blazar, M.D is a Pediatrics healthcare provider based in Minneapolis, Minnesota. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/23/2006. The National Provider Identifier (NPI) number assigned to this provider is 1003842162.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Bruce Blazar, M.D has received a total of $1.1M in payments from pharmaceutical and medical device companies, with $297,853 received in 2024. These payments were reported across 84 transactions from 12 companies. The most common payment nature is "Acquisitions" ($1.1M).

Practice Information

  • Specialty Pediatrics
  • Other Specialties Pediatric Hematology-Oncology
  • Location Minneapolis, MN
  • Active Since 06/23/2006
  • Last Updated 10/24/2012
  • Taxonomy Code 208000000X
  • Entity Type Individual
  • NPI Number 1003842162

Products in Payments

  • ORENCIA (Biological) $6,692
  • REZUROCK (Drug) $4,395

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Pediatrics Doctors in Minneapolis